Although the use of gold salts in the treatment of rheumatoid arthritis is well established, the mode of action is still not known. The finding that gold is taken up by synovial tissue macrophages and accumulates in the lysosomes (Persellin and Ziff, 1966) has led to speculation that perhaps it acts either by lysosome stabilization, as does hydrocortisone (Weissmann and Thomas, 1963) , or by the inhibition of the lysosomal enzymes, acid phosphatase, /J-glucuronidase, and cathepsin, as is known to occur in vitro (Ennis, Granda, and Posner, 1968 
Although the use of gold salts in the treatment of rheumatoid arthritis is well established, the mode of action is still not known. The finding that gold is taken up by synovial tissue macrophages and accumulates in the lysosomes (Persellin and Ziff, 1966) has led to speculation that perhaps it acts either by lysosome stabilization, as does hydrocortisone (Weissmann and Thomas, 1963) , or by the inhibition of the lysosomal enzymes, acid phosphatase, /J-glucuronidase, and cathepsin, as is known to occur in vitro (Ennis, Granda, and Posner, 1968) . These mechanisms would presuppose a site of action of gold within the synovial membrane and cavity. Yet information on the quantitative aspects of gold deposition in the body during chrysotherapy is scanty, and such data as there are suggest that the bulk of the gold both in man (Gottlieb, Smith, and Smith, 1972) and in animals (Betrand, Waine, and Tobias, 1948) is selectively concentrated in the lymph nodes, liver, and bone marrow, with relatively small concentrations in articular structures. This report concerns a study of tissue gold concentrations in synovium, striated muscle, bone, and fat in patients who have received chrysotherapy, and is part of a larger study set up to attempt to define those factors which might improve the success rate of this form of therapy. 
DETERMINATION OF TISSUE GOLD LEVELS
Tissue samples (300-500 mg) were weighed into tared porcelain crucibles and dry-ashed overnight at 450°C. The crucibles were re-weighed after cooling, and the residues were dissolved in 1-0 ml of 0-1 N nitric acid solution.
Gold levels in tissue digests were measured by comparison with gold chloride standard solution (0-500 pg/100 ml in 0-1 N HNO3), using a Perkin-Elmer Model 303 Atomic absorption spectrophotometer. Results were expressed as pg gold/g wet weight tissue.
Results (Tables)
In each of the three comparisons (synovium/muscle, synovium/bone, and synovium/fat) the patients were divided into two groups. Group I consisted of patients who were currently receiving gold injections, the mean interval since last injection was measured in weeks. Group II consisted of patients who had not received gold injections for some years. Fortunately, the mean total dose of gold administered to the two groups was similar in each of the three comparisons. Table I shows a comparison of synovial gold levels with those in striated muscle. In group I, comprising five patients, the ratio of the mean of the synovial levels to the mean of the muscle levels was 8-05:1, whereas in group II, comprising six patients, the corresponding ratio was 0-45:1. Using Wilcoxon's nonparametric ranking test on the synovial: muscle *ratios for individual patients in the two groups, the difference between the two groups was significant at the 1 % level. Tables II and III show the results of the synovium/bone and synovium/fat content, respectively. The ratio of the mean synovium gold ratio to that of bone and fat in group I was 8-75 and 15-8, whereas in group lI the corresponding ratios were 0-92 and 14, respectively. However, using the same statistical technique as with the synovial/muscle comparison, the difference between groups I and II was not statistically significant in either case.
Discussion
Recent years have seen a number of attempts to place chrysotherapy on a more rational basis in order to improve efficacy and minimize side effects. Most workers have concentrated on measuring serum gold levels, but despite two reports to the contrary (Krusius, Markkanen, and Peltola, 1970; Lorber, Atkins, Chang, Lee, Starrs, and Bovy, 1973) , the overwhelming weight of opinion (Gerber, Paulus, Bluestone, and Pearson, 1972; Jessop and Johns, 1973; Lidsky, Sharp, Duffy, Masri, and Seibert, 1973; Yamanaka, Miyagi, Mita, and Yamasaki, 1973) , including our own (Billings, Grahame, Marks, Wood, and Taylor, 1974) , is that clinical response does not relate to circulating blood gold levels. As yet little attention has been paid to tissue levels.
Clearly tissue gold levels are unlikely to prove a practicable procedure in monitoring gold therapy in individual patients, but their study could help to elucidate some of the mystery that enshrouds gold therapy at the present time. Of factors likely to influence gold deposition in synovial membrane, both the total dose of gold salt injected and the interval since the last injection are likely to be important. In the present study, by taking groups whose mean total dose of gold injected was almost identical, it was possible to 'neutralize' the effect of total dose and thereby show the substantial fall that occurs in synovial tissue concentration of gold when injections are discontinued. This may explain the well known observation that relapse sometimes occurs when chrysotherapy is discontinued and may be obviated by continuous 'maintenance' therapy (Ziff and Baum, 1972) . Furthermore, by the concurrent analysis of specimens of a nonarticular tissue, i.e. striated muscle, bone, or fat, it has been possible to show seeming selective deposition of gold in synovial tissue during 'active' chrysotherapy. It has yet to be determined whether there is selective retention ofgold in muscle, bone, and fat, or preferential loss of gold from the synovium, after chrysotherapy has been discontinued.
Summary
Tissue gold concentrations were measured in specimens of synovium, striated muscle, bone, and fat obtained at operation from groups of patients suffering from rheumatoid arthritis who had received a similar mean total dose of gold by intramuscular injection. In the groups ofpatients who were currently receiving injections the mean synovial gold level exceeded the muscle, bone, and fat gold levels by ratios of 8 05, 8 75, and 15-80, respectively, whereas in the groups of patients whose chrysotherapy had been discontinued some years earlier the corresponding ratios were 045, 0-92, and 1N4, respectively.
These Nunn and Tribe (1963) to this Society many years ago dealing with two patients in whom the gold was not only demonstrable in lymphatic channels in muscle by photohistochemical methods, but was visible in plain radiographs of the upper arm muscles taken many years after the last injection of gold, thus providing another instance of its persistence in large quantities.
DR. BILLINGS I think this is one of the points of the paper. Muscle does seem to be more selective in its concentration of gold than other tissues. DR. BILLINGS I would think that one of the dangers of putting gold straight into the synovial fluid is that it may not be the same form of gold as that injected into muscle and then transported to the joint. I think that it is the nature of the transported gold which is little understood, and we are following this up with the University of Surrey in order to see whether we can finally identify the nature of sodium aurothiomalate (Myocrisin) after injection and its arrival at tissue sites. So I think it would be wrong to assume that you were doing the same intra-articularly as intramuscularly.
DR. M. MCMAHON (Cork) In relation to Dr. Glyn's remark, I have used it on ten cases intra-articularly in knee joints. The most recent case had trouble with one knee and I gave him 10 mg on one occasion to the knee joint. He has been symptom free now for 6 months. I have done this on at least seven or eight occasions and each time the knee joint seemed to be the most successful. I tried it on shoulder and wrist joints, but the knee joint seems to respond the best. 
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